StockMarketWire.com - Clinical stage biotechnology company ValiRx said it shareholders had rejected a recapitalisation plan at a general meeting that would have allowed it to issue new shares.

The company had warned last month that it had limited financial resources and would be unable to continue a clinical trial programme without fresh capital.

'The directors are considering their options to resolve this situation,' ValiRx said.


At 2:10pm: [LON:VAL] ValiRx PLC share price was -0.03p at 0.05p



Story provided by StockMarketWire.com